Riskpilot← Back to searchSign inGet full accessAllerga AB
ABActiveOrg 5591365308Verkstadsgatan 1Traditional, complementary and alternative medicine activities · NACE 8696Est. 20171 employees
Revenue 2025
SEK 1,2M
0% vs 2024
EBITDA margin
11.1%
+34% vs 2024
Equity ratio
73.7%
Financial strength
Net profit 2025
SEK 110K
+76% vs 2024
| Revenue | SEK 1,2M | +0% |
| EBITDA | SEK 134K | +34% |
| Net profit | SEK 110K | +76% |
| Total assets | SEK 461K | +4% |
| Equity | SEK 340K | +3% |
| Employees | 1 | — |
Legal name
Allerga AB
Org number
5591365308
Legal form
Aktiebolag
NACE code
8696 · Traditional, complementary and alternative medicine activities
Founded
1 december 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utredning och behandling av hälsoproblem med hjälp av Bioresonansterapi, utbildning inom Bioresonansterapi samt därmed förenlig verksamhet. Bolaget skall även bedriva konsultverksamhet som montör inom inredning och därmed förenlig verksamhet.
Address
Verkstadsgatan 1
Email
markus@allerga.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 846 | 1 261 | 1 195 | 1 198 | 1 202 |
| Staff expenses | — | −773 | −819 | −808 | −810 |
| EBITDA | 164 | 159 | 94 | 100 | 134 |
| Depreciation & amort. | −87 | −92 | −10 | −23 | — |
| EBIT | 77 | 67 | 84 | 77 | 134 |
| Net financials | −10 | −11 | −1 | 2 | 4 |
| Profit before tax | 67 | 57 | 84 | 79 | 138 |
| Tax | −13 | −13 | −17 | −16 | −28 |
| Net profit | 54 | 44 | 67 | 62 | 110 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 487 | 552 | 386 | 443 | 461 |
| Equity | 157 | 201 | 267 | 330 | 340 |
| Long-term debt | 220 | 183 | 0 | — | — |
| Short-term debt | 110 | 169 | 119 | 113 | 121 |
| Total debt | 330 | 352 | 119 | 113 | 121 |
EBITDA margin
11.1%
This company
15.8%
Market median
-30% vs market
20212025
Equity ratio
73.7%
This company
38.2%
Market median
+93% vs market
20212025
Return on equity
32.3%
This company
18.4%
Market median
+76% vs market
20212025
Net profit margin
9.1%
This company
8.1%
Market median
+12% vs market
20212025
Asset turnover
2.61×
This company
1.12×
Market median
+133% vs market
20212025
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Allerga AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Josefin Eriksson | Deputy Board Member | 0 companies |
| Markus Johan Peter Johansson | Board of Directors | 0 companies |